G'day Jaggin, maybe this is a rose coloured glasses thing but I actually find the disclosure quite positive and in line with the way that Baker carries himself and this company - he's a straight shooter.
First the first time ever in the history of bio-spec companies you have these guys coming out and saying we're not happy with some technical issues associated with the contract research orgs in-mouse trials and that they want the trial to be repeated. Good on them. Good quality control and good science by my read.
Ann: Update on ALA-101 and onCARlytics research collaboration, page-11
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
14.0¢ |
Change
-0.005(3.45%) |
Mkt cap ! $147.0M | |||
| Open | High | Low | Value | Volume |
| 14.5¢ | 15.0¢ | 14.0¢ | $95.42K | 662.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 168013 | 14.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.0¢ | 1440985 | 13 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| ALA (ASX) Chart |